Vol. 53 | No. 1 | January-June 2025Back

Open Access

The Effect of Sulodexide on the Incidence of Cardiovascular Outcomes in Patients With Vascular Disorders

Eugenio B. Reyes, Paula Victoria Catherine Y. Cheng-Bromeo, Nigel Jeronimo C. Santos
May 2025 DOI 10.69944/pjc.06659058d5

More Info

Eugenio B. Reyes, MD1 | Paula Victoria Catherine Y. Cheng-Bromeo, MD1,2 | Nigel Jeronimo C. Santos, MD1

1 Division of Cardiovascular Medicine, Department of Medicine, University of the Philippines – Philippine General Hospital

2 Section of Electrophysiology and Cardiac Pacing, Division of Cardiovascular Medicine, Department of Medicine, University of the Philippines – Philippine General Hospital

 

Correspondence:

Nigel Jeronimo Santos

Email: nigel.jeronimo.santos@gmail.com

 

DISCLOSURE: This paper was not funded by any pharmaceutical company. Dr Reyes receives honorarium for lectures for Corbridge Philippines, the distributor of sulodexide.

References
  1. Rinde LB, Lind C, Småbrekke B, Njølstad I, Mathiesen EB, Wilsgaard T, et al. Impact of incident myocardial infarction on the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost [Internet]. 2016;14(6):1183–91. Available from: http://dx.doi.org/10.1111/jth.13329
  2. Srensen HT, Horvath-Puho E, Pedersen L. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. The Lancet. 2007;370:1773–9.
  3. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA [Internet]. 2010;304(12):1350–7. Available from: http://dx.doi.org/10.1001/jama.2010.1322
  4. Xie J, Ikram MK, Cotch MF, Klein B, Varma R, Shaw JE, et al. Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: A systematic review and meta-analysis. JAMA Ophthalmol [Internet]. 2017;135(6):586. Available from: http://dx.doi.org/10.1001/jamaophthalmol.2017.0988
  5. Wehner P, Nitardy W. Chronic kidney disease and acute myocardial infarction: The story after 1 year. J Am Heart Assoc [Internet]. 2016;5(5). Available from: http://dx.doi.org/10.1161/JAHA.116.003626
  6. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA [Internet]. 2001;286(4):421–6. Available from: http://dx.doi.org/10.1001/jama.286.4.421
  7. Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol [Internet]. 2012;25(3):235–42. Available from: http://dx.doi.org/10.1016/j.beha.2012.06.007
  8. Sleight P. The HOPE study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst [Internet]. 2000;1(1):18–20. Available from: http://dx.doi.org/10.3317/jraas.2000.002
  9. Castilla-Guerra L, Fernandez-Moreno MDC, Leon-Jimenez D, Rico-Corral MA. Statins in ischemic stroke prevention: What have we learned in the post-SPARCL (the stroke prevention by aggressive reduction in cholesterol levels) decade? Curr Treat Options Neurol [Internet]. 2019;21(5):22. Available from: http://dx.doi.org/10.1007/s11940-019-0563-4
  10. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet [Internet]. 2011;377(9784):2181–92. Available from: http://dx.doi.org/10.1016/S0140-6736(11)60739-3
  11. Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, et al. Prevention of stroke with ticagrelor in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54 (prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54): Circulation [Internet]. 2016;134(12):861–71. Available from: http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024637
  12. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet [Internet]. 2005;366(9489):895–906. Available from: http://dx.doi.org/10.1016/S0140-6736(05)67185-1
  13. Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: A systematic review and meta-analyses. Clin Ther [Internet]. 2017;39(7):1456-1478.e36. Available from: http://dx.doi.org/10.1016/j.clinthera.2017.05.358
  14. Mohammedi K, Woodward M, Marre M, Colagiuri S, Cooper M, Harrap S, et al. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovasc Diabetol [Internet]. 2017;16(1):95. Available from: http://dx.doi.org/10.1186/s12933-017-0574-y
  15. Broekhuizen LN, Mooij HL, Kastelein JJP, Stroes ESG, Vink H, Nieuwdorp M. Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease. Curr Opin Lipidol [Internet]. 2009;20(1):57–62. Available from: http://dx.doi.org/10.1097/MOL.0b013e328321b587
  16. Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther [Internet]. 2013;8:49–65. Available from: http://dx.doi.org/10.2147/DDDT.S6762
  17. Song JH, Chin HS, Kwon OW. Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS). Graefe’s Archive for Clinical and Experimental Ophthalmology. 2015;253:829–37.
  18. Gambaro G, Kinalska I, Oksa A, Pont’uch P, Hertlová M, Olsovsky J, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial: The Di.N.a.s. randomized trial. J Am Soc Nephrol [Internet]. 2002;13(6):1615–25. Available from: http://dx.doi.org/10.1097/01.asn.0000014254.87188.e5
  19. Condorelli M, Chiariello M, Dagianti A, Penco M, Dalla Volta S, Pengo V, et al. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol [Internet]. 1994;23(1):27–34. Available from: http://dx.doi.org/10.1016/0735-1097(94)90498-7
  20. Errichi BM, Cesarone MR, Belcaro G, Marinucci R, Ricci A, Ippolito A, et al. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology [Internet]. 2004;55(3):243–9. Available from: http://dx.doi.org/10.1177/000331970405500302
  21. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V, et al. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost. 2002;87(6):947–52.
  22. Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V. Arterial arm of the Suavis (Sulodexide Arterial Venous Italian Study) group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J [Internet]. 2002;23(13):1057–65. Available from: http://dx.doi.org/10.1053/euhj.2001.3033
  23. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol [Internet]. 2012;23(1):123–30. Available from: http://dx.doi.org/10.1681/ASN.2011040378
  24. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis [Internet]. 2011;58(5):729–36. Available from: http://dx.doi.org/10.1053/j.ajkd.2011.06.020
  25. Heerspink HL, Greene T, Lewis JB, Raz I, Rohde RD, Hunsicker LG, et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant [Internet]. 2008;23(6):1946–54. Available from: http://dx.doi.org/10.1093/ndt/gfm893
  26. Bang K, Chin HJ, Chae DW, Joo KW, Kim YS, Kim S, et al. Anti-proteinuric effect of sulodexide in immunoglobulin A nephropathy. Yonsei Med J [Internet]. 2011;52(4):588–94. Available from: http://dx.doi.org/10.3349/ymj.2011.52.4.588
  27. Satirapoj B, Kaewput W, Supasyndh O, Ruangkanchanasetr P. Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial. J Diabetes Res [Internet]. 2015;2015:172038. Available from: http://dx.doi.org/10.1155/2015/172038
  28. Bikdeli B, Chatterjee S, Kirtane AJ, Parikh SA, Andreozzi GM, Desai NR, et al. Sulodexide versus control and the risk of thrombotic and hemorrhagic events: Meta-analysis of randomized trials. Semin Thromb Hemost [Internet]. 2020;46(8):908–18. Available from: http://dx.doi.org/10.1055/s-0040-1716874
  29. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS). Eur Heart J [Internet]. 2018;39(9):763–816. Available from: http://dx.doi.org/10.1093/eurheartj/ehx095
  30. Silvestro L, Lanzarotti E, Marchi E, Gori M, Pescador R, Ferro L, et al. Human pharmacokinetics of glycosaminoglycans using deuterium-labeled and unlabeled substances: evidence for oral absorption. Semin Thromb Hemost [Internet]. 1994;20(3):281–92. Available from: http://dx.doi.org/10.1055/s-2007-1001914
  31. Bignamini AA, Chebil A, Gambaro G, Matuška J. Sulodexide for diabetic-induced disabilities: A systematic review and meta-analysis. Adv Ther [Internet]. 2021;38(3):1483–513. Available from: http://dx.doi.org/10.1007/s12325-021-01620-1
  32. Cha JJ, Kang YS, Hyun YY, Han SY, Jee YH, Han KH, et al. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats. Life Sci [Internet]. 2013;92(23):1118–24. Available from: http://dx.doi.org/10.1016/j.lfs.2013.04.008
  33. Ligi D, Benitez S, Croce L, Rivas-Urbina A, Puig N, Ordóñez-Llanos J, et al. Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation: Inhibitory effect of glycosaminoglycan sulodexide. Biochim Biophys Acta Mol Basis Dis [Internet]. 2018;1864(12):3559–67. Available from: http://dx.doi.org/10.1016/j.bbadis.2018.09.022
  34. Giurdanella G, Lazzara F, Caporarello N, Lupo G, Anfuso CD, Eandi CM, et al. Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE. Biochem Pharmacol [Internet]. 2017;142:145–54. Available from: http://dx.doi.org/10.1016/j.bcp.2017.06.130
  35. De Felice F, Megiorni F, Pietrantoni I, Tini P, Lessiani G, Mastroiacovo D, et al. Sulodexide counteracts endothelial dysfunction induced by metabolic or non-metabolic stresses through activation of the autophagic program. Eur Rev Med Pharmacol Sci [Internet]. 2019;23(6):2669–80. Available from: http://dx.doi.org/10.26355/eurrev_201903_17415
  36. Gabryel B, Jarząbek K, Machnik G, Adamczyk J, Belowski D, Obuchowicz E, et al. Superoxide dismutase 1 and glutathione peroxidase 1 are involved in the protective effect of sulodexide on vascular endothelial cells exposed to oxygen-glucose deprivation. Microvasc Res [Internet]. 2016;103:26–35. Available from: http://dx.doi.org/10.1016/j.mvr.2015.10.001
  37. Masola V, Onisto M, Zaza G, Lupo A, Gambaro G. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med [Internet]. 2012;10(1):213. Available from: http://dx.doi.org/10.1186/1479-5876-10-213
  38. Song JW, Zullo JA, Liveris D, Dragovich M, Zhang XF, Goligorsky MS. Therapeutic restoration of endothelial glycocalyx in sepsis. J Pharmacol Exp Ther [Internet]. 2017;361(1):115–21. Available from: http://dx.doi.org/10.1124/jpet.116.239509
  39. Ligi D, Mosti G, Croce L, Raffetto JD, Mannello F. Chronic venous disease – Part I: Inflammatory biomarkers in wound healing. Biochim Biophys Acta Mol Basis Dis [Internet]. 2016;1862(10):1964–74. Available from: http://dx.doi.org/10.1016/j.bbadis.2016.07.018
  40. Mannello F, Ligi D, Canale M, Raffetto JD. Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease. Curr Vasc Pharmacol [Internet]. 2014;12(1):173–85. Available from: http://dx.doi.org/10.2174/1570161111666131126144025
  41. Mannello F, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014;33(3):236–42.
  42. Bernardo E, Guevarra V, Cloma L. Experience with the use of sulodexide (vessel due F) and pentoxifyline (Trental) in patients with vasculopathic cranial nerve daisies. UERMMMC Journal of Health Sciences. 2007;14–6.
  43. Balagapo MA, Vega J, Perez M. Sulodexide program on acute coronary syndrome (SUPREME Study). Philipp J Cardiol. 2005;117–21.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.